Form 4: LVTX Director Oliger Reports Option Cancellation

LAVA Therapeutics director Christy J. Oliger reported the cancellation of 33,390 share options in exchange for cash and contingent value rights.

Summary

• Christy J. Oliger, a director of LAVA Therapeutics NV, reported a change in beneficial ownership.
• 33,390 share options, with an exercise price of $0.93, were cancelled on November 13, 2025.
• The cancellation was executed pursuant to a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• In exchange for the options, Oliger received cash and Contingent Value Rights (CVRs).
• The cash component was calculated as the excess of $1.04 over the per share exercise price, multiplied by the total number of shares underlying the option, resulting in approximately $3,672.90 (net of applicable withholding tax and other deductions).
• Oliger also received one CVR per share underlying the options, totaling 33,390 CVRs.
• Following this transaction, Oliger beneficially owns 0 derivative securities.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider transaction, providing factual details without inherently positive or negative implications for the company's operational performance or future prospects.

Positives

• The director received cash and Contingent Value Rights (CVRs) for in-the-money share options, indicating a realized gain on the options.

Negatives

• The director no longer holds these specific share options, reducing their direct equity exposure in the company through this particular instrument.

Future Outlook

na

Industry Context

na

Related Party Transactions

• The cancellation of share options was executed pursuant to a Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation.

Stakeholder Impact

• Minor impact on shareholders due to a director's change in equity holdings, as the options were cancelled in exchange for cash and contingent value rights.

Key Dates

Keywords

LAVA Therapeutics, LVTX, Form 4, insider transaction, stock options, director, beneficial ownership, XOMA Royalty Corporation, CVRs